Sevillano Angel M, Gutiérrez Eduardo, Yuste Claudia, Cavero Teresa, Mérida Evangelina, Rodríguez Paola, García Ana, Morales Enrique, Fernández Cristina, Martínez Miguel Angel, Moreno Juan Antonio, Praga Manuel
Departments of Nephrology and.
Research and Clinical Epidemiology Unit, Department of Preventive Medicine, Hospital Clinic, San Carlos, Madrid, Spain.
J Am Soc Nephrol. 2017 Oct;28(10):3089-3099. doi: 10.1681/ASN.2017010108. Epub 2017 Jun 7.
Hematuria is a cardinal symptom in IgA nephropathy, but its influence on the risk of disease progression has been scarcely investigated. We followed a cohort of 112 patients with IgA nephropathy for a mean±SEM period of 14±10.2 years, during which clinical and analytic risk factors (including urine sediment examination) were regularly recorded. According to the magnitude of time-averaged hematuria, we classified patients as those with persistent hematuria and those with negative or minimal hematuria. We also classified patients according to the magnitude of time-averaged proteinuria (>0.75 or ≤0.75 g/d). The proportion of patients reaching ESRD or a 50% reduction of renal function was significantly greater among patients with persistent hematuria than patients with minimal or negative hematuria (30.4% and 37.0% versus 10.6% and 15.2%, respectively; =0.01). Multivariable analysis revealed time-averaged hematuria, time-averaged proteinuria, renal function at baseline, and the presence of tubulointerstitial fibrosis on renal biopsy as independent predictors of ESRD. After hematuria disappearance, which occurred in 46% of the patients, the rate of renal function decline changed from -6.45±14.66 to -0.18±2.56 ml/min per 1.73 m per year (=0.001). Patients with time-averaged proteinuria >0.75 g/d had significantly poorer renal survival than those with time-averaged proteinuria ≤0.75 g/d. However, on further classification by time-averaged hematuria, only those patients with time-averaged proteinuria >0.75 g/d and persistent hematuria had significantly worse renal survival than those in the other three groups. In conclusion, remission of hematuria may have a significant favorable effect on IgA nephropathy outcomes.
血尿是IgA肾病的主要症状,但对其疾病进展风险的影响鲜有研究。我们对112例IgA肾病患者进行了平均±标准误为14±10.2年的随访,在此期间定期记录临床和分析风险因素(包括尿沉渣检查)。根据平均血尿时间的程度,我们将患者分为持续性血尿患者和血尿阴性或微量血尿患者。我们还根据平均蛋白尿程度(>0.75或≤0.75 g/d)对患者进行分类。持续性血尿患者中达到终末期肾病(ESRD)或肾功能降低50%的患者比例显著高于微量或阴性血尿患者(分别为30.4%和37.0%,对比10.6%和15.2%;P=0.01)。多变量分析显示,平均血尿时间、平均蛋白尿时间、基线肾功能以及肾活检时肾小管间质纤维化的存在是ESRD的独立预测因素。46%的患者血尿消失后,肾功能下降速率从-6.45±14.66降至-0.18±2.56 ml/min/1.73 m²/年(P=0.001)。平均蛋白尿>0.75 g/d的患者肾脏生存率显著低于平均蛋白尿≤0.75 g/d的患者。然而,根据平均血尿时间进一步分类后,只有平均蛋白尿>0.75 g/d且持续性血尿的患者肾脏生存率显著低于其他三组。总之,血尿缓解可能对IgA肾病的预后有显著的有利影响。